Top 5 Undervalued Stocks To Invest In 2019


My Top Pick for speculators for the coming year is a biotech company, explains leading growth and income stock specialist Crista Huff, editor of Cabot Undervalued Stocks Advisor.

Vertex Pharmaceuticals (VRTX) is prominent for its world-leading treatments for cystic fibrosis. Vertex is expected to outperform its peers in earnings growth through 2020.

Vertex is expected to report earnings per share of $2.27 in 2017 (December year-end), reflecting 195% earnings growth. This aggressive growth stock has a 2017 price/earnings ratio of 34.

As you know, pharmaceutical stocks got left behind in investors’ post-election race to own financial and basic industry stocks.

But the benefit of sector rotations is that we get to buy shares of healthy, growing companies while their prices are low.

In December, the company announced that it had come to a pricing and reimbursement agreement with Germany on Orkambi, a Vertex treatment for cystic fibrosis. This is bullish news.

Top 5 Undervalued Stocks To Invest In 2019: Nationstar Mortgage Holdings Inc.(NSM)


Advisors’ Opinion:

  • [By Joseph Griffin]

    Schwab Charles Investment Management Inc. lifted its position in Nationstar Mortgage Holdings Inc (NYSE:NSM) by 4.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 149,406 shares of the financial services provider’s stock after buying an additional 5,824 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Nationstar Mortgage were worth $2,684,000 as of its most recent filing with the SEC.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Nationstar Mortgage (NSM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Eqis Capital Management Inc. purchased a new stake in Nationstar Mortgage Holdings Inc (NYSE:NSM) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,391 shares of the financial services provider’s stock, valued at approximately $182,000.

Top 5 Undervalued Stocks To Invest In 2019: Inuvo, Inc(INUV)


Advisors’ Opinion:

  • [By Stephan Byrd]

    Bard Associates Inc. lifted its stake in Inuvo Inc (NYSEAMERICAN:INUV) by 1,003.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,533,471 shares of the technology company’s stock after acquiring an additional 1,394,471 shares during the period. Bard Associates Inc.’s holdings in Inuvo were worth $1,185,000 as of its most recent filing with the Securities and Exchange Commission.

Top 5 Undervalued Stocks To Invest In 2019: REGENXBIO Inc.(RGNX)


Advisors’ Opinion:

  • [By Todd Campbell]

    There are lots of exciting biotech stocks that investors can consider owning in their growth portfolios. But according to Motley Fool Industry Focus: Healthcare analyst Shannon Jones and Fool contributor Todd Campbell, Neurocrine Biosciences (NASDAQ:NBIX) and Regenxbio (NASDAQ:RGNX) are two stocks that ought to be top of mind.

  • [By Todd Campbell]

    Earlier this year, Novartis acquired AveXis for $8.7 billion to land AVXS-101, a potential one-and-done gene therapy for SMA. Using technology licensed from RegenXbio (NASDAQ: RGNX), one dose of AVXS-101 could restore SMN production by inserting a functioning copy of the missing or mutated SMN gene in motor neurons.

  • [By George Budwell, Chuck Saletta, and Todd Campbell]

    Armed with this insight, we asked three of our Motley Fool contributors which top small-cap stocks have their attention right now. They named AcelRx Pharmaceuticals (NASDAQ:ACRX), Realogy Holdings (NYSE:RLGY),  and Regenxbio Inc. (NASDAQ:RGNX). Read on to find out why. 

  • [By Todd Campbell, Keith Speights, and Brian Feroldi]

    Biotechnology stocks can pop or drop because of clinical trial successes or failures, and that makes investing in biotech stocks riskier than investing in other industries. Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes stocks like Regenxbio (NASDAQ:RGNX), Regeneron Pharmaceuticals (NASDAQ:REGN), and AbbVie (NYSE:ABBV) worth considering. Read on to learn more about these companies and why some of our Motley Fools think they could be top stocks to add to portfolios this month.

  • [By Keith Speights]

    Three gene therapy stocks have really stood out in the first half of the year. Sarepta Therapeutics (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), and Regnxbio (NASDAQ:RGNX) stocks have soared 120% or more since the beginning of 2018. Here’s what has made these the best gene therapy stocks of 2018 so far — and a look at whether or not they have even more room to run.

  • [By Todd Campbell]

    The programs address a variety of rare indications that collectively represent about 10,000 children. Because rare genetic disease therapies command six-figure prices, this acquisition could result in medicines that move the needle someday. However, there’s no guarantee these programs will pan out, and competitors are also working on gene therapies for these indications. For example, Regenxbio (NASDAQ:RGNX) announced it’s using its proprietary AAV vectors to create a gene therapy for Batten disease it hopes to usher into human trials next year.

Top 5 Undervalued Stocks To Invest In 2019: iShares Nasdaq Biotechnology Index Fund(IBB)


Advisors’ Opinion:

  • [By Stephan Byrd]

    Cahill Financial Advisors Inc. acquired a new position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,926 shares of the financial services provider’s stock, valued at approximately $212,000.

  • [By Jim Crumly]

    Industrial stocks suffered the biggest losses, with the Industrial Select SPDR ETF (NYSEMKT:XLI) dropping 2.1%. Biotech shares had a good day, though; the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) rose 1.5%.

  • [By Dan Caplinger]

    For those who prefer not to try to pick individual stocks, exchange-traded funds can be a valuable alternative. In particular, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) offers a diversified portfolio of biotech stocks that gives you complete coverage of the sector. Since going through a major downturn in 2015 and early 2016, the biotech sector has bounced back. With that in mind, let’s take a closer look at the iShares biotech ETF to see whether it would make a smart buy right now.

  • [By Jim Crumly]

    Biotech stocks surged, with the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) rising 1.8%. The retail sector was weak; the SPDR S&P Retail ETF (NYSEMKT:XRT) slipped 0.7%. 

  • [By Jim Crumly]

    Biotech continued its summer rally, with the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) jumping 1.3%. The price of crude oil appeared poised to regain the $70 level, rising 1.7% and pushing the energy sector higher; the SPDR S&P Oil & Gas Exploration & Production ETF (NYSEMKT:XOP) closed up 1.3%. 

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) – a good measure of small-cap biotech stocks – gained almost 6% yesterday. Meanwhile, the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) jumped almost 4%. The biotech buying frenzy helped lift the Nasdaq Composite to a gain of almost 1% in Monday’s session.

Top 5 Undervalued Stocks To Invest In 2019: Lazard World Dividend & Income Fund, Inc.(LOR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Headlines about Lazard World Dividend & Income Fund, Inc common stock (NYSE:LOR) have trended somewhat negative this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lazard World Dividend & Income Fund, Inc common stock earned a media sentiment score of -0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 48.1658217953419 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Leave a Reply

Your email address will not be published.